Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -39.33
- Piotroski Score 2.00
- Grade Neutral
- Symbol (AMTI)
- Company Applied Molecular Transport Inc.
- Price $0.26
- Changes Percentage (-3.13%)
- Change -$0.01
- Day Low $0.26
- Day High $0.31
- Year High $0.84
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $1.70
- High Stock Price Target $3.00
- Low Stock Price Target $0.40
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.89
- Trailing P/E Ratio -0.13915343915344
- Forward P/E Ratio -0.13915343915344
- P/E Growth -0.13915343915344
- Net Income $-125,431,000
